Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2023

Open Access 01-12-2023 | Hepatocellular Carcinoma | Review

The interplay between noncoding RNAs and drug resistance in hepatocellular carcinoma: the big impact of little things

Authors: Yuan Fang, XiaoLi Zhang, HanFei Huang, Zhong Zeng

Published in: Journal of Translational Medicine | Issue 1/2023

Login to get access

Abstract

Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death in people, and a common primary liver cancer. Lacking early diagnosis and a high recurrence rate after surgical resection, systemic treatment is still an important treatment method for advanced HCC. Different drugs have distinct curative effects, side effects and drug resistance due to different properties. At present, conventional molecular drugs for HCC have displayed some limitations, such as adverse drug reactions, insensitivity to some medicines, and drug resistance. Noncoding RNAs (ncRNAs), including microRNAs (miRNAs), long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs), have been well documented to be involved in the occurrence and progression of cancer. Novel biomarkers and therapeutic targets, as well as research into the molecular basis of drug resistance, are urgently needed for the management of HCC. We review current research on ncRNAs and consolidate the known roles regulating drug resistance in HCC and examine the potential clinical applications of ncRNAs in overcoming drug resistance barriers in HCC based on targeted therapy, cell cycle non-specific chemotherapy and cell cycle specific chemotherapy.
Literature
1.
2.
3.
Llovet JM, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(5):293–313.PubMedCrossRef
4.
Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. 2020;371: m3544.PubMedCrossRef
5.
Beaufrère A, Calderaro J, Paradis V. Combined hepatocellular-cholangiocarcinoma: An update. J Hepatol. 2021;74(5):1212–24.PubMedCrossRef
6.
Zhong L, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6(1):201.PubMedPubMedCentralCrossRef
7.
Tang W, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5(1):87.PubMedPubMedCentralCrossRef
8.
Haider T, et al. Drug resistance in cancer: mechanisms and tackling strategies. Pharmacol Rep. 2020;72(5):1125–51.PubMedCrossRef
9.
10.
Li B, et al. Surmounting cancer drug resistance: New insights from the perspective of N(6)-methyladenosine RNA modification. Drug Resist Updat. 2020;53: 100720.PubMedCrossRef
11.
Veldman J, et al. Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma. Cancer Treat Rev. 2020;82: 101931.PubMedCrossRef
12.
13.
14.
Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018;18(1):5–18.PubMedCrossRef
15.
16.
17.
18.
19.
20.
21.
Ghafouri-Fard S, et al. A review on the role of PCA3 lncRNA in carcinogenesis with an especial focus on prostate cancer. Pathol Res Pract. 2022;231: 153800.PubMedCrossRef
22.
23.
Guo S, et al. LncRNA PCA3 promotes antimony-induced lipid metabolic disorder in prostate cancer by targeting MIR-132-3 P/SREBP1 signaling. Toxicol Lett. 2021;348:50–8.PubMedCrossRef
24.
Llovet JM, et al. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616.PubMedCrossRef
25.
Pan G, et al. EMT-associated microRNAs and their roles in cancer stemness and drug resistance. Cancer Commun (Lond). 2021;41(3):199–217.PubMedCrossRef
26.
27.
Li Y, et al. Bmi-1-induced miR-27a and miR-155 promote tumor metastasis and chemoresistance by targeting RKIP in gastric cancer. Mol Cancer. 2020;19(1):109.PubMedPubMedCentralCrossRef
28.
Li Y, et al. circRNA circARNT2 suppressed the sensitivity of hepatocellular carcinoma cells to cisplatin by targeting the miR-155-5p/PDK1 axis. Mol Ther Nucleic Acids. 2021;23:244–54.PubMedCrossRef
29.
Van Roosbroeck K, et al. Combining anti-Mir-155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res. 2017;23(11):2891–904.PubMedCrossRef
30.
31.
Jauhari A, Yadav S. MiR-34 and MiR-200: regulator of cell fate plasticity and neural development. Neuromolecular Med. 2019;21(2):97–109.PubMedCrossRef
32.
33.
Naghizadeh S, et al. The role of miR-34 in cancer drug resistance. J Cell Physiol. 2020;235(10):6424–40.PubMedCrossRef
34.
35.
36.
37.
38.
Azmi AS, Bao B, Sarkar FH. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev. 2013;32(3–4):623–42.PubMedCrossRef
39.
40.
Álvarez-Garcia V, et al. Mechanisms of PTEN loss in cancer: It’s all about diversity. Semin Cancer Biol. 2019;59:66–79.PubMedCrossRef
41.
Fu X, et al. Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway. J Exp Clin Cancer Res. 2018;37(1):52.PubMedPubMedCentralCrossRef
42.
Kong FH, et al. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Theranostics. 2021;11(11):5464–90.PubMedPubMedCentralCrossRef
43.
44.
Papadopoulos N, Lennartsson J. The PDGF/PDGFR pathway as a drug target. Mol Aspects Med. 2018;62:75–88.PubMedCrossRef
45.
46.
Cheng Z, Wei-Qi J, Jin D. New insights on sorafenib resistance in liver cancer with correlation of individualized therapy. Biochim Biophys Acta Rev Cancer. 2020;1874(1): 188382.PubMedCrossRef
47.
Zhu AX. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma. Expert Opin Investig Drugs. 2010;19(5):663–72.PubMedCrossRef
48.
49.
El-Khoueiry AB, et al. Cabozantinib: an evolving therapy for hepatocellular carcinoma. Cancer Treat Rev. 2021;98: 102221.PubMedCrossRef
50.
Ai L, et al. Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management. Expert Rev Clin Pharmacol. 2019;12(12):1121–7.PubMedCrossRef
51.
52.
53.
Pollutri D, et al. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma. Cell Death Dis. 2018;9(1):4.PubMedPubMedCentralCrossRef
54.
Chen M, et al. miR-6071 inhibits hepatocellular carcinoma progression via targeting PTPN11. Arch Biochem Biophys. 2022;727: 109345.PubMedCrossRef
55.
Wei Y, et al. miR-3154 promotes hepatocellular carcinoma progression via suppressing HNF4α. Carcinogenesis. 2022;43(10):1002–14.PubMedCrossRef
56.
He X, et al. Hsa-miR-4277 decelerates the metabolism or clearance of sorafenib in HCC cells and enhances the sensitivity of HCC cells to sorafenib by targeting cyp3a4. Front Oncol. 2021;11: 735447.PubMedPubMedCentralCrossRef
57.
Li TT, et al. MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway. J Biomed Sci. 2021;28(1):56.PubMedPubMedCentralCrossRef
58.
Feng X, et al. MiR-25 enhances autophagy and promotes sorafenib resistance of hepatocellular carcinoma via targeting FBXW7. Int J Med Sci. 2022;19(2):257–66.PubMedPubMedCentralCrossRef
59.
Enkhnaran B, et al. microRNA-106b-5p promotes cell growth and sensitizes chemosensitivity to sorafenib by targeting the BTG3/Bcl-xL/p27 signaling pathway in hepatocellular carcinoma. J Oncol. 2022;2022:1971559.PubMedPubMedCentralCrossRef
60.
Zhang Z, et al. The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma. Cell Death Dis. 2020;11(10):902.PubMedPubMedCentralCrossRef
61.
Long HD, et al. Reduced hsa-miR-124-3p levels are associated with the poor survival of patients with hepatocellular carcinoma. Mol Biol Rep. 2018;45(6):2615–23.PubMedCrossRef
62.
Dong ZB, et al. MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1. Cell Death Dis. 2022;13(1):35.PubMedPubMedCentralCrossRef
63.
Fornari F, et al. Elucidating the molecular basis of sorafenib resistance in HCC: current findings and future directions. J Hepatocell Carcinoma. 2021;8:741–57.PubMedPubMedCentralCrossRef
64.
65.
66.
Wang N, et al. microRNA-23a in human cancer: its roles, mechanisms and therapeutic relevance. Cancers (Basel). 2018;11(1):7.PubMedCrossRef
67.
Lu Y, et al. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma. J Exp Clin Cancer Res. 2022;41(1):3.PubMedPubMedCentralCrossRef
68.
Xi J, Ma CX. Sequencing endocrine therapy for metastatic breast cancer: what do we do after disease progression on a CDK4/6 inhibitor? Curr Oncol Rep. 2020;22(6):57.PubMedCrossRef
69.
70.
Stupp R, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306–16.PubMedPubMedCentralCrossRef
71.
72.
73.
Wang H, et al. Long non-coding RNA placenta-specific protein 2 regulates the chemosensitivity of cancer cells to cisplatin in hepatocellular carcinoma (HCC) by sponging microRNA-96 to upregulate X-linked inhibitor of apoptosis protein. Bioengineered. 2022;13(4):10765–73.PubMedPubMedCentralCrossRef
74.
Meng X, et al. The role of non-coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential. Cancer Commun (Lond). 2021;41(10):981–1006.PubMedCrossRef
75.
76.
77.
Zou L, Sun P, Zhang L. miR-651-3p enhances the sensitivity of hepatocellular carcinoma to cisplatin via targeting ATG3-mediated cell autophagy. J Oncol. 2021;2021:5391977.PubMedPubMedCentralCrossRef
78.
Zeng T, et al. Upregulation of miR-138 increases sensitivity to cisplatin in hepatocellular carcinoma by regulating EZH2. Biomed Res Int. 2021;2021:6665918.PubMedPubMedCentralCrossRef
79.
Bao Y, et al. Overexpression of microRNA-9 enhances cisplatin sensitivity in hepatocellular carcinoma by regulating EIF5A2-mediated epithelial-mesenchymal transition. Int J Biol Sci. 2020;16(5):827–37.PubMedPubMedCentralCrossRef
80.
Xu Y, Wang H, Gao W. MiRNA-610 acts as a tumour suppressor to depress the cisplatin resistance in hepatocellular carcinoma through targeted silencing of hepatoma-derived growth factor. Arch Med Sci. 2020;16(6):1394–401.PubMedCrossRef
81.
Chen S, et al. miR-21-5p suppressed the sensitivity of hepatocellular carcinoma cells to cisplatin by targeting FASLG. DNA Cell Biol. 2019;38(8):865–73.PubMedCrossRef
82.
Lin CC, et al. Safety and preliminary efficacy of ramucirumab in combination with FOLFOX4 in patients with advanced hepatocellular carcinoma: a nonrandomized, open-label, Phase IB Study. Oncologist. 2020;25(12):e1921–9.PubMedCrossRef
83.
Li M, et al. Cost-effectiveness analysis of hepatic arterial infusion of FOLFOX combined sorafenib for advanced hepatocellular carcinoma with portal vein invasion. Front Oncol. 2021;11: 562135.PubMedPubMedCentralCrossRef
84.
Ren WW, et al. MicroRNA-125b reverses oxaliplatin resistance in hepatocellular carcinoma by negatively regulating EVA1A mediated autophagy. Cell Death Dis. 2018;9(5):547.PubMedPubMedCentralCrossRef
85.
Cao F, Yin LX. miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway. Exp Mol Pathol. 2019;106:34–43.PubMedCrossRef
86.
Schwabe RF, Greten TF. Gut microbiome in HCC—mechanisms, diagnosis and therapy. J Hepatol. 2020;72(2):230–8.PubMedCrossRef
87.
88.
Xie C, et al. A hMTR4-PDIA3P1-miR-125/124-TRAF6 regulatory axis and its function in nf kappa B signaling and chemoresistance. Hepatology. 2020;71(5):1660–77.PubMedCrossRef
89.
Duan H, et al. Recent advances in drug delivery systems for targeting cancer stem cells. Acta Pharm Sin B. 2021;11(1):55–70.PubMedCrossRef
90.
Wang J, et al. MicroRNA-135a promotes proliferation, migration, invasion and induces chemoresistance of endometrial cancer cells. Eur J Obstet Gynecol Reprod Biol X. 2020;5: 100103.PubMedCrossRef
91.
Wei XC, et al. Hepatitis B core antigen modulates exosomal miR-135a to target vesicle-associated membrane protein 2 promoting chemoresistance in hepatocellular carcinoma. World J Gastroenterol. 2021;27(48):8302–22.PubMedPubMedCentralCrossRef
92.
Chen E, et al. miR-26b enhances the sensitivity of hepatocellular carcinoma to Doxorubicin via USP9X-dependent degradation of p53 and regulation of autophagy. Int J Biol Sci. 2021;17(3):781–95.PubMedPubMedCentralCrossRef
93.
94.
95.
96.
97.
Barata PC, Sartor AO. Metastatic castration-sensitive prostate cancer: abiraterone, docetaxel, or…. Cancer. 2019;125(11):1777–88.PubMedCrossRef
98.
Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68(2):116–32.PubMedCrossRef
99.
Wang Y, et al. The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer. Expert Opin Drug Metab Toxicol. 2021;17(3):291–306.PubMedCrossRef
100.
101.
Huang Y, et al. Inhibition of microRNA-16 facilitates the paclitaxel resistance by targeting IKBKB via NF-κB signaling pathway in hepatocellular carcinoma. Biochem Biophys Res Commun. 2018;503(2):1035–41.PubMedCrossRef
102.
Yang J, Cui R, Liu Y. MicroRNA-212-3p inhibits paclitaxel resistance through regulating epithelial-mesenchymal transition, migration and invasion by targeting ZEB2 in human hepatocellular carcinoma. Oncol Lett. 2020;20(4):23.PubMedPubMedCentral
103.
Lyu N, et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1). J Clin Oncol. 2022;40(5):468–80.PubMedCrossRef
104.
Sethy C, Kundu CN. 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair inhibition. Biomed Pharmacother. 2021;137: 111285.PubMedCrossRef
105.
Siddiqui NS, et al. Capecitabine for the treatment of pancreatic cancer. Expert Opin Pharmacother. 2019;20(4):399–409.PubMedCrossRef
106.
Pinyopornpanish K, et al. Chemopreventive effect of statin on hepatocellular carcinoma in patients with nonalcoholic steatohepatitis cirrhosis. Am J Gastroenterol. 2021;116(11):2258–69.PubMedCrossRef
107.
108.
Goyal L, et al. A phase ii and biomarker study of sorafenib combined with modified FOLFOX in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2019;25(1):80–9.PubMedCrossRef
109.
Vodenkova S, et al. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future. Pharmacol Ther. 2020;206: 107447.PubMedCrossRef
110.
Shao P, et al. MicroRNA-205-5p regulates the chemotherapeutic resistance of hepatocellular carcinoma cells by targeting PTEN/JNK/ANXA3 pathway. Am J Transl Res. 2017;9(9):4300–7.PubMedPubMedCentral
111.
Zheng RP, et al. MiR-145 regulates the chemoresistance of hepatic carcinoma cells against 5-fluorouracil by targeting toll-like receptor 4. Cancer Manag Res. 2020;12:6165–75.PubMedPubMedCentralCrossRef
112.
113.
Ai L, Xu A, Xu J. Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond. Adv Exp Med Biol. 2020;1248:33–59.PubMedCrossRef
114.
Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58–67.PubMedCrossRef
115.
Bu MT, et al. The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors. Pharmacol Ther. 2022;240:108211.PubMedCrossRef
116.
117.
Adams S, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):405–11.PubMedCrossRef
118.
Hamid O, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582–8.PubMedPubMedCentralCrossRef
119.
120.
Iqbal MA, et al. MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance. Mol Aspects Med. 2019;70:3–20.PubMedCrossRef
121.
Zhang G, et al. microRNA-4717 differentially interacts with its polymorphic target in the PD1 3’ untranslated region: a mechanism for regulating PD-1 expression and function in HBV-associated liver diseases. Oncotarget. 2015;6(22):18933–44.PubMedPubMedCentralCrossRef
122.
Liu J, et al. Endoplasmic reticulum stress causes liver cancer cells to release exosomal miR-23a-3p and Up-regulate programmed death ligand 1 expression in macrophages. Hepatology. 2019;70(1):241–58.PubMedCrossRef
123.
124.
125.
Tan YT, et al. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer. Cancer Commun (Lond). 2021;41(2):109–20.PubMedCrossRef
126.
Cabral LKD, Tiribelli C, Sukowati CHC. Sorafenib resistance in hepatocellular carcinoma: the relevance of genetic heterogeneity. Cancers (Basel). 2020;12(6):1576.PubMedCrossRef
127.
Zheng ZQ, et al. Long noncoding RNA FAM225A promotes nasopharyngeal carcinoma tumorigenesis and metastasis by acting as ceRNA to sponge miR-590-3p/miR-1275 and upregulate ITGB3. Cancer Res. 2019;79(18):4612–26.PubMedCrossRef
128.
129.
Zhang J, et al. KCNQ1OT1 contributes to sorafenib resistance and programmed death-ligand-1-mediated immune escape via sponging miR-506 in hepatocellular carcinoma cells. Int J Mol Med. 2020;46(5):1794–804.PubMedPubMedCentral
130.
Chen YT, et al. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m(6)A methylation promotes disease progression and sorafenib resistance. Hum Cell. 2021;34(6):1800–11.PubMedCrossRef
131.
Shi Y, et al. HANR enhances autophagy-associated sorafenib resistance through miR-29b/ATG9A axis in hepatocellular carcinoma. Onco Targets Ther. 2020;13:2127–37.PubMedPubMedCentralCrossRef
132.
Chen Y, et al. LINC01234/MicroRNA-31-5p/MAGEA3 axis mediates the proliferation and chemoresistance of hepatocellular carcinoma cells. Mol Ther Nucleic Acids. 2020;19:168–78.PubMedCrossRef
133.
Ding H, et al. Long non-coding RNA TPTEP1 inhibits hepatocellular carcinoma progression by suppressing STAT3 phosphorylation. J Exp Clin Cancer Res. 2019;38(1):189.PubMedPubMedCentralCrossRef
134.
Zhao G, et al. Long non-coding RNA LINC00173 enhances cisplatin resistance in hepatocellular carcinoma via the microRNA-641/RAB14 axis. Oncol Lett. 2021;21(5):371.PubMedPubMedCentralCrossRef
135.
Mei J, et al. Long noncoding RNA TINCR facilitates hepatocellular carcinoma progression and dampens chemosensitivity to oxaliplatin by regulating the miR-195-3p/ST6GAL1/NF-κB pathway. J Exp Clin Cancer Res. 2022;41(1):5.PubMedPubMedCentralCrossRef
136.
Kang X, et al. Silenced LINC01134 enhances oxaliplatin sensitivity by facilitating ferroptosis through GPX4 in hepatocarcinoma. Front Oncol. 2022;12: 939605.PubMedPubMedCentralCrossRef
137.
Ma L, et al. LSD1-demethylated LINC01134 confers oxaliplatin resistance through SP1-induced p62 transcription in HCC. Hepatology. 2021;74(6):3213–34.PubMedCrossRef
138.
139.
Yang Y, et al. Long non-coding RNA FGD5-AS1 contributes to cisplatin resistance in hepatocellular carcinoma via sponging microRNA-153-3p by upregulating Twinfilin Actin Binding Protein 1 (TWF1). Bioengineered. 2021;12(1):6713–23.PubMedPubMedCentralCrossRef
140.
Shu G, et al. LINC00680 enhances hepatocellular carcinoma stemness behavior and chemoresistance by sponging miR-568 to upregulate AKT3. J Exp Clin Cancer Res. 2021;40(1):45.PubMedPubMedCentralCrossRef
141.
Xu F, et al. Overexpressing lncRNA SNHG16 inhibited HCC proliferation and chemoresistance by functionally sponging hsa-miR-93. Onco Targets Ther. 2018;11:8855–63.PubMedPubMedCentralCrossRef
142.
143.
Shi F, et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer. 2011;128(4):887–96.PubMedCrossRef
144.
Segura-Bayona S, Stracker TH. The Tousled-like kinases regulate genome and epigenome stability: implications in development and disease. Cell Mol Life Sci. 2019;76(19):3827–41.PubMedCrossRef
145.
Zhan T, et al. Construction of novel lncRNA-miRNA-mRNA network associated with recurrence and identification of immune-related potential regulatory axis in hepatocellular carcinoma. Front Oncol. 2021;11: 626663.PubMedPubMedCentralCrossRef
146.
Zhong F, et al. LncRNA AC099850.3 promotes hepatocellular carcinoma proliferation and invasion through PRR11/PI3K/AKT axis and is associated with patients prognosis. J Cancer. 2022;13(3):1048–60.PubMedPubMedCentralCrossRef
147.
Sun Z, et al. LINC00244 suppresses cell growth and metastasis in hepatocellular carcinoma by downregulating programmed cell death ligand 1. Bioengineered. 2022;13(3):7635–47.PubMedPubMedCentralCrossRef
148.
Zeng C, et al. HOXA-AS3 promotes proliferation and migration of hepatocellular carcinoma cells via the miR-455-5p/PD-L1 axis. J Immunol Res. 2021;2021:9289719.PubMedPubMedCentralCrossRef
149.
Qi F, et al. Tumor mutation burden-associated LINC00638/miR-4732-3p/ULBP1 axis promotes immune escape via PD-L1 in hepatocellular carcinoma. Front Oncol. 2021;11: 729340.PubMedPubMedCentralCrossRef
150.
Song H, et al. Long noncoding RNA CASC11 promotes hepatocarcinogenesis and HCC progression through EIF4A3-mediated E2F1 activation. Clin Transl Med. 2020;10(7): e220.PubMedPubMedCentralCrossRef
151.
152.
153.
154.
155.
Tokunaga R, et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation—a target for novel cancer therapy. Cancer Treat Rev. 2018;63:40–7.PubMedCrossRef
156.
Huang XY, et al. Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis. Mol Cancer. 2020;19(1):92.PubMedPubMedCentralCrossRef
157.
Zhang PF, et al. Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma. Mol Cancer. 2020;19(1):110.PubMedPubMedCentralCrossRef
158.
Liu D, et al. circKCNN2 suppresses the recurrence of hepatocellular carcinoma at least partially via regulating miR-520c-3p/methyl-DNA-binding domain protein 2 axis. Clin Transl Med. 2022;12(1): e662.PubMedPubMedCentralCrossRef
159.
Gogry FA, et al. Current update on intrinsic and acquired colistin resistance mechanisms in bacteria. Front Med (Lausanne). 2021;8: 677720.PubMedCrossRef
160.
161.
162.
163.
Samaridou E, Heyes J, Lutwyche P. Lipid nanoparticles for nucleic acid delivery: Current perspectives. Adv Drug Deliv Rev. 2020;154–155:37–63.PubMedCrossRef
164.
Gupta A, et al. Nucleic acid delivery for therapeutic applications. Adv Drug Deliv Rev. 2021;178: 113834.PubMedCrossRef
165.
Kulkarni JA, et al. The current landscape of nucleic acid therapeutics. Nat Nanotechnol. 2021;16(6):630–43.PubMedCrossRef
166.
Pereira-Silva M, et al. Micelleplexes as nucleic acid delivery systems for cancer-targeted therapies. J Control Release. 2020;323:442–62.PubMedCrossRef
167.
Barbieri I, Kouzarides T. Role of RNA modifications in cancer. Nat Rev Cancer. 2020;20(6):303–22.PubMedCrossRef
168.
Giri P, et al. Chemical modification of enzymes to improve biocatalytic performance. Biotechnol Adv. 2021;53: 107868.PubMedCrossRef
169.
170.
Zhang Y, et al. Inhibition of miR-15a-5p promotes the chemoresistance to pirarubicin in hepatocellular carcinoma via targeting eIF4E. Comput Math Methods Med. 2021;2021:6468405.PubMedPubMedCentralCrossRef
171.
172.
Cheng Z, et al. MicroRNA-92b augments sorafenib resistance in hepatocellular carcinoma via targeting PTEN to activate PI3K/AKT/mTOR signaling. Braz J Med Biol Res. 2021;54(9): e10390.PubMedPubMedCentralCrossRef
173.
Li X, et al. Silencing lncRNA HCG18 regulates GPX4-inhibited ferroptosis by adsorbing miR-450b-5p to avert sorafenib resistance in hepatocellular carcinoma. Hum Exp Toxicol. 2023;42:9603271221142818.PubMedCrossRef
174.
Kong H, et al. Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3. Bioengineered. 2022;13(2):3108–21.PubMedPubMedCentralCrossRef
175.
Lin JC, Yang PM, Liu TP. PERK/ATF4-dependent ZFAS1 upregulation is associated with sorafenib resistance in hepatocellular carcinoma cells. Int J Mol Sci. 2021;22(11):5848.PubMedPubMedCentralCrossRef
176.
Sun J, et al. LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells. Acta Biochim Biophys Sin (Shanghai). 2022;54(2):261–70.PubMedCrossRef
177.
Berhane T, et al. Knockdown of the long noncoding RNA PURPL induces apoptosis and sensitizes liver cancer cells to doxorubicin. Sci Rep. 2022;12(1):19502.PubMedPubMedCentralCrossRef
178.
Li Y, et al. The lncARSR/PTEN/Akt/nuclear factor-kappa B feedback regulatory loop contributes to doxorubicin resistance in hepatocellular carcinoma. J Biochem Mol Toxicol. 2022;36(9): e23119.PubMedCrossRef
179.
180.
Yu T, et al. MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis. Cell Oncol (Dordr). 2021;44(4):821–34.PubMedCrossRef
181.
Qiu R, Zeng Z. Hsa_circ_0006988 promotes sorafenib resistance of hepatocellular carcinoma by modulating IGF1 using miR-15a-5p. Can J Gastroenterol Hepatol. 2022;2022:1206134.PubMedPubMedCentralCrossRef
182.
Yang Q, Wu G. CircRNA-001241 mediates sorafenib resistance of hepatocellular carcinoma cells by sponging miR-21-5p and regulating TIMP3 expression. Gastroenterol Hepatol. 2022;45(10):742–52.PubMedCrossRef
183.
Li P, et al. circMRPS35 promotes malignant progression and cisplatin resistance in hepatocellular carcinoma. Mol Ther. 2022;30(1):431–47.PubMedCrossRef
184.
Dong ZR, et al. CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity. Mol Cancer. 2021;20(1):75.PubMedPubMedCentralCrossRef
Metadata
Title
The interplay between noncoding RNAs and drug resistance in hepatocellular carcinoma: the big impact of little things
Authors
Yuan Fang
XiaoLi Zhang
HanFei Huang
Zhong Zeng
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2023
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-023-04238-9

Other articles of this Issue 1/2023

Journal of Translational Medicine 1/2023 Go to the issue

Research

Altered insulin secretion dynamics relate to oxidative stress and inflammasome activation in children with obesity and insulin resistance

Review

Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect

Research

Single protein encapsulated SN38 for tumor-targeting treatment

Research

The role of TET2-mediated ROBO4 hypomethylation in the development of diabetic retinopathy

Research

Targeting epigenetic features in clear cell sarcomas based on patient-derived cell lines

Research

Targeting choroidal vasculopathy via up-regulation of tRNA-derived fragment tRF-22 expression for controlling progression of myopia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits